Molecular structure of Pazopanib, CAS Number: 444731-52-6
Pazopanib (CAS 444731-52-6)
See product citations (2)
Alternate Names:
GW-786034; 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide
Application:
Pazopanib is a potent and selective inhibitor of Flk-1, PDGFR and c-kit
CAS Number:
444731-52-6
Purity:
≥98%
Molecular Weight:
437.52
Molecular Formula:
C21H23N7O2S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Pazopanib is a potent and selective multi-targeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (Flk-1), platelet-derived growth factor receptor (PDGFR) and c-kit, which are key proteins responsible for tumor growth and angiogenesis. As a multi-targeted receptor tyrosine kinase inhibitor (RTKi), it has been specifically designed to target various RTKs, including vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs). By binding to these RTKs, Pazopanib effectively obstructs their ability to phosphorylate downstream target proteins. Consequently, the activation of downstream signaling pathways is prevented, ultimately leading to the inhibition of tumor cell growth and angiogenesis.
Pazopanib (CAS 444731-52-6) References
- The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. | Balagula, Y., et al. 2012. Invest New Drugs. 30: 1773-81. PMID: 21394443
- Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. | Isham, CR., et al. 2013. Sci Transl Med. 5: 166ra3. PMID: 23283368
- Pazopanib in sarcomas: expanding the PALETTE. | Wilky, BA., et al. 2013. Curr Opin Oncol. 25: 373-8. PMID: 23666473
- Pazopanib versus sunitinib in metastatic renal-cell carcinoma. | Motzer, RJ., et al. 2013. N Engl J Med. 369: 722-31. PMID: 23964934
- Pazopanib, a promising option for the treatment of aggressive fibromatosis. | Szucs, Z., et al. 2017. Anticancer Drugs. 28: 421-426. PMID: 28099210
- Pazopanib-induced Endothelial Injury with Podocyte Changes. | Maruyama, K., et al. 2018. Intern Med. 57: 987-991. PMID: 29269661
- Pazopanib-Induced Hepatotoxicity in an Experimental Rat Model. | Cetin, B., et al. 2018. Chemotherapy. 63: 39-45. PMID: 29393107
- A metabolomic perspective of pazopanib-induced acute hepatotoxicity in mice. | Wang, YK., et al. 2019. Xenobiotica. 49: 655-670. PMID: 29897827
- Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38. | Iwase, M., et al. 2019. Cancer Chemother Pharmacol. 83: 993-998. PMID: 30810774
- Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma. | Harada, Y., et al. 2020. BMJ Case Rep. 13: PMID: 32641305
- Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature. | Fanelli, M., et al. 2021. J Oncol Pharm Pract. 27: 766-770. PMID: 32838682
- Protective effects of taxifolin on pazopanib-induced liver toxicity: an experimental rat model. | Akagunduz, B., et al. 2021. Exp Anim. 70: 169-176. PMID: 33239495
- A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy. | Shiri, P., et al. 2022. Mol Divers. 26: 2981-3002. PMID: 35235141
- Pazopanib restricts small cell lung cancer proliferation via reactive oxygen species-mediated endoplasmic reticulum stress. | Li, Y., et al. 2022. Thorac Cancer. 13: 2421-2428. PMID: 35866204
- Pazopanib-laden lipid based nanovesicular delivery with augmented oral bioavailability and therapeutic efficacy against non-small cell lung cancer. | Nadaf, SJ., et al. 2022. Int J Pharm. 628: 122287. PMID: 36257467
Inhibitor of:
2900053A13Rik, 3Gn-T6, 4922501L14Rik, 4930408F14Rik, 4933416I08Rik, 7530416G11Rik, AI182371, AI316807, ALG11, AMBP, AML-2, Angptl1, ASPH, BAALC, BAI-1, BB114814, BC021395, BC049730, BSPH1, c-Kit, C11orf94, C20orf160, C5orf34_4833420G17Rik, CASKIN2, CCT B, CD93, CEACAM19, CEACAM20, CLEC-14A, CLLD6, CMS, CNK1, CT47B1, Cxx1b, CYHR1, DCIR2, dcTRAILR2, DLEC1, Dok-4, Dok-5, E-Ras, EG-VEGF, EGFL6, ETL, FAK, FAXC, Fes, FHL-5, FIP1L1, Flk-1, FLTR1, GAPT, GGH, Gm14325, Gm3336, Gm447, GPR172C, Grap, H2-Kk, HCCA2, Hepatocellular Carcinoma Marker, IGSF10, ILEI, Isthmin, KIAA1522, KKIAMRE, KNP-I, LERK-3, LOC440087, LOC641696, LOC647238, MAGE-A12, MAGE-C3, MAP17, Mare, MAST1, MPND, MSE55, NARF, NBPF7, neuropilin, NF2, Niban, NK10, Olfr157, Olfr208, Olr1002, Olr1060, Olr110, Olr1126, Olr1199, Olr1203, Olr1220, Olr1231, Olr1257, Olr1264, Olr1286, Olr129, Olr1293, Olr1295, Olr1307, Olr1320, Olr1321, Olr1323, Olr1330, Olr1331, Olr1334, Olr1350, Olr1385, Olr1397, Olr1404, Olr1528, Olr153, Olr1560, Olr1561, Olr1576, Olr1630, Olr1641, Olr165, Olr1704, Olr1718, Olr1733, Olr175, Olr185, Olr223, Olr232, Olr233, Olr272, Olr309, Olr354, Olr361, Olr367, Olr375, Olr390, Olr440, Olr496, Olr500, Olr507, Olr526, Olr554, Olr569, Olr575, Olr592, Olr598, Olr607, Olr608, Olr690, Olr707, Olr72, Olr736, Olr750, Olr769, Olr772, Olr788, Olr83, Olr889, Olr92, Olr920, Olr943, Olr956, Olr962, Olr964, Olr996, OTTMUSG00000004968, OTTMUSG00000019138, OVCA1, p-Tyr, PATE-N, PDGF-A, PDGFR, PDGFR-beta, PHIP, PIG-F, PL6, Ppp2r3d, Prolifera, Proliferin-1, Proliferin-4, PRR11, PTP-MEG2, RASGEF1A, Renal Cell Carcinoma, RGL1, RNF213, robo4, Rse, RUSC2, Sad-1, SBK1, SCGBL, SEF14, Sfta2, SGS2, Shc4, Skint9, Sm D1, Spot-2, Srb4, ST, SUP, TCP-c, TEL, TEM7, TEM7R, TMEM114, Trav13d-4, Trav2, Trav3n-2, TREM-2b, TREM-2c, Txk, Tyrosine Kinase, UGT1A5, V1RI6, Vasohibin-2, vasostatin II, VEGF, VEGF-D, VG5Q, VHR, Vmn1r191, Vmn1r57, Vmn2r27, Vmn2r5, Vmn2r60, VSIG10, Zfp804b, ZNF397OS, ZNF720, and ZNF730.Activator of:
PlGF, and Vasohibin-1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Pazopanib, 25 mg | sc-396318 | 25 mg | $130.00 | |||
Pazopanib, 50 mg | sc-396318A | 50 mg | $182.00 |